Latest Breaking News On - Valgerdur sigurdardottir - Page 1 : comparemela.com

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

Uppsala lanValgerdur sigurdardottirAmerican college of rheumatologyArthritis foundationUppsala universityFalun hospitalAmerican collegePsoriasis areaSeverity indexAccessed octoberPsoriatic arthritisCost effectiveDisease modifying antirheumatic drugsTnf inhibitor